A new clinical trial listing for mazdutide was posted on August 28, 2026. The trial, titled "Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity," is registered under identifier NCT07657676.
The study is listed as Phase 4 and its current status is not yet recruiting. According to the registry entry, the trial aims to examine mazdutide in patients who have both coronary atherosclerosis and overweight or obesity.
No results or outcome data have been posted for this trial at this time. Mazdutide remains classified as an unapproved compound under research and is not approved for general use. This update reflects only the trial's registration status as of the listed date, and no conclusions about safety or effectiveness can be drawn from a not yet recruiting listing.
Readers interested in more background on mazdutide can refer to the compound overview for further context.